Oxygen Development LLC
Deerfield Beach, FL, United States
Due-diligence reportFind an accredited testing lab and confirm its scope covers your product and methods.
Oxygen Development LLC is a dietary supplement manufacturer in Deerfield Beach, FL, United States, certified to NSF/ANSI 455-2 GMP, with 2 manufacturing facilities on NSF’s public NSF/ANSI 455 listing as of November 19, 2026. Listed dosage forms: soft chews & chewables and gummies.
- Website
- oxygendevelopment.com
- Phone
- 954-480-2675
- Facilities listed
- 2
- Last checked
Dosage forms
- Soft chews & chewables
- Gummies
As listed in the product categories of this company’s NSF/ANSI 455-2 certified facilities.
Certified facilities
Manufacturing (2)
1441 W Newport Center Drive, Deerfield Beach, FL 33442, United States
- Coating
- Liquid Formulation
- Mixing
- Molding
- Packaging/Labeling Operation
- Packaging/Labeling Operation - Bulk Packaging
- Quality Unit Operations
- Warehousing
1525 S Congress Avenue, Palm Springs, FL 33406, United States
- Packaging/Labeling Operation
- Packaging/Labeling Operation - Primary Packaging
- Packaging/Labeling Operation - Secondary Packaging
- Quality Unit Operations
- Warehousing
How Oxygen Development LLC compares
Among the 769 manufacturers we list, as of our last check.
- One of 22 gummy manufacturers we list in Florida, and 116 in the United States. All gummy manufacturers in the USA · All in Florida
- One of 2 chewable manufacturers we list in Florida, and 7 in the United States.
- NSF lists molding at one of its facilities, an operation listed for 121 of the 769 manufacturers we list.
- Has 2 listed manufacturing or packaging facilities; 71% of the manufacturers we list have fewer.
FDA recall records
No food or dietary supplement recall found under the name Oxygen Development LLC in FDA’s enforcement reports, as of .
We match FDA records by company name only. A recall listed under a different name won’t appear here, and a different company with the same name could. FDA’s food enforcement records start in June 2012. How we check
FDA inspections
FDA lists 6 food or dietary supplement inspections at facilities matching Oxygen Development LLC, from 2009 to 2026, as of . 4 found no objectionable conditions and 2 found conditions the firm was left to correct.
No action indicated · No objectionable conditions found
Inspected
Palm Springs, Florida
Listed by FDA as Oxygen Development, L.L.C.
FEI 3009461317
No action indicated · No objectionable conditions found
Inspected
Palm Springs, Florida
Listed by FDA as Oxygen Development, L.L.C.
FEI 3009461317
No action indicated · No objectionable conditions found
Inspected
Palm Springs, Florida
Listed by FDA as Oxygen Development, L.L.C.
3 citations posted:
- Procedures not in writing, fully followed (21 CFR 211.22(d))
- Absence of Written Procedures (21 CFR 211.100(a))
- Annual visual exams of drug products (21 CFR 211.170(b))
Full citation text
Procedures not in writing, fully followed (21 CFR 211.22(d))
The responsibilities and procedures applicable to the quality control unit are not fully followed.
Absence of Written Procedures (21 CFR 211.100(a))
There are no written procedures for production and process controls designed to assure that the drug products have the identity, strength, quality, and purity they purport or are represented to possess.
Annual visual exams of drug products (21 CFR 211.170(b))
Reserve samples from representative sample lots or batches of drug products selected by acceptable statistical procedures are not examined visually at least once a year for evidence of deterioration.
FEI 3009461317
Voluntary action indicated · Objectionable conditions found; FDA left corrections to the firm
Inspected
Palm Springs, Florida
Listed by FDA as Oxygen Development, L.L.C.
13 citations posted:
- Procedures not in writing, fully followed (21 CFR 211.22(d))
- Disposition recorded by lot identification (21 CFR 211.80(d))
- SOPs not followed / documented (21 CFR 211.100(b))
- Actual vs. theoretical yields not determined (21 CFR 211.103)
See all 13 citations
Procedures not in writing, fully followed (21 CFR 211.22(d))
The responsibilities and procedures applicable to the quality control unit are not fully followed.
Disposition recorded by lot identification (21 CFR 211.80(d))
The distinctive code for each lot of drug product containers and closures is not used in recording the disposition of each lot.
SOPs not followed / documented (21 CFR 211.100(b))
Written production and process control procedures are not followed in the execution of production and process control functions.
Actual vs. theoretical yields not determined (21 CFR 211.103)
Actual yield and percentages of theoretical yield are not determined at the conclusion of each appropriate phase of manufacturing of the drug product.
Control procedures fail to include the following (21 CFR 211.110(a))
Control procedures fail to include dissolution time and rate.
Procedures for non-sterile drug products (21 CFR 211.113(a))
Procedures designed to prevent objectionable microorganisms in drug products not required to be sterile are not established.
Label reconciliation discrepancies evaluation/investigation (21 CFR 211.125(c))
Discrepancies found outside preset limits when reconciling the quantities of labeling issued, used and returned, were not investigated.
Failing drug products not rejected (21 CFR 211.165(f))
Drug products failing to meet established specifications are not rejected.
Testing in same container - closure system (21 CFR 211.166(a)(4))
The written stability program does not assure testing of the drug product in the same container-closure system as that in which the drug product is marketed.
Annual visual exams of drug products (21 CFR 211.170(b))
Reserve samples from representative sample lots or batches of drug products selected by acceptable statistical procedures are not examined visually at least once a year for evidence of deterioration.
Signature and checking of records -- 2 persons (21 CFR 211.186(a))
The master production and control records for each batch size of drug product are not prepared, dated, and signed by one person with a full handwritten signature and independently checked, dated, and signed by a second person.
Prepared for each batch, include complete information (21 CFR 211.188)
Batch production and control records do not include complete information relating to the production and control of each batch.
Quality control unit review of records (21 CFR 211.192)
Drug product production and control records, are not reviewed and approved by the quality control unit to determine compliance with all established, approved written procedures before a batch is released or distributed.
FEI 3009461317
Voluntary action indicated · Objectionable conditions found; FDA left corrections to the firm
Inspected
Palm Springs, Florida
Listed by FDA as Oxygen Development, L.L.C.
FEI 3009461317
Show all 6 inspections
No action indicated · No objectionable conditions found
Inspected
Palm Springs, Florida
Listed by FDA as Oxygen Development, L.L.C.
FEI 3009461317
No action indicated · No objectionable conditions found
Inspected
Palm Springs, Florida
Listed by FDA as Oxygen Development, L.L.C.
FEI 3009461317
No action indicated · No objectionable conditions found
Inspected
Palm Springs, Florida
Listed by FDA as Oxygen Development, L.L.C.
3 citations posted:
- Procedures not in writing, fully followed (21 CFR 211.22(d))
- Absence of Written Procedures (21 CFR 211.100(a))
- Annual visual exams of drug products (21 CFR 211.170(b))
Full citation text
Procedures not in writing, fully followed (21 CFR 211.22(d))
The responsibilities and procedures applicable to the quality control unit are not fully followed.
Absence of Written Procedures (21 CFR 211.100(a))
There are no written procedures for production and process controls designed to assure that the drug products have the identity, strength, quality, and purity they purport or are represented to possess.
Annual visual exams of drug products (21 CFR 211.170(b))
Reserve samples from representative sample lots or batches of drug products selected by acceptable statistical procedures are not examined visually at least once a year for evidence of deterioration.
FEI 3009461317
Voluntary action indicated · Objectionable conditions found; FDA left corrections to the firm
Inspected
Palm Springs, Florida
Listed by FDA as Oxygen Development, L.L.C.
13 citations posted:
- Procedures not in writing, fully followed (21 CFR 211.22(d))
- Disposition recorded by lot identification (21 CFR 211.80(d))
- SOPs not followed / documented (21 CFR 211.100(b))
- Actual vs. theoretical yields not determined (21 CFR 211.103)
See all 13 citations
Procedures not in writing, fully followed (21 CFR 211.22(d))
The responsibilities and procedures applicable to the quality control unit are not fully followed.
Disposition recorded by lot identification (21 CFR 211.80(d))
The distinctive code for each lot of drug product containers and closures is not used in recording the disposition of each lot.
SOPs not followed / documented (21 CFR 211.100(b))
Written production and process control procedures are not followed in the execution of production and process control functions.
Actual vs. theoretical yields not determined (21 CFR 211.103)
Actual yield and percentages of theoretical yield are not determined at the conclusion of each appropriate phase of manufacturing of the drug product.
Control procedures fail to include the following (21 CFR 211.110(a))
Control procedures fail to include dissolution time and rate.
Procedures for non-sterile drug products (21 CFR 211.113(a))
Procedures designed to prevent objectionable microorganisms in drug products not required to be sterile are not established.
Label reconciliation discrepancies evaluation/investigation (21 CFR 211.125(c))
Discrepancies found outside preset limits when reconciling the quantities of labeling issued, used and returned, were not investigated.
Failing drug products not rejected (21 CFR 211.165(f))
Drug products failing to meet established specifications are not rejected.
Testing in same container - closure system (21 CFR 211.166(a)(4))
The written stability program does not assure testing of the drug product in the same container-closure system as that in which the drug product is marketed.
Annual visual exams of drug products (21 CFR 211.170(b))
Reserve samples from representative sample lots or batches of drug products selected by acceptable statistical procedures are not examined visually at least once a year for evidence of deterioration.
Signature and checking of records -- 2 persons (21 CFR 211.186(a))
The master production and control records for each batch size of drug product are not prepared, dated, and signed by one person with a full handwritten signature and independently checked, dated, and signed by a second person.
Prepared for each batch, include complete information (21 CFR 211.188)
Batch production and control records do not include complete information relating to the production and control of each batch.
Quality control unit review of records (21 CFR 211.192)
Drug product production and control records, are not reviewed and approved by the quality control unit to determine compliance with all established, approved written procedures before a batch is released or distributed.
FEI 3009461317
Voluntary action indicated · Objectionable conditions found; FDA left corrections to the firm
Inspected
Palm Springs, Florida
Listed by FDA as Oxygen Development, L.L.C.
FEI 3009461317
No action indicated · No objectionable conditions found
Inspected
Palm Springs, Florida
Listed by FDA as Oxygen Development, L.L.C.
4 citations posted:
- Testing and release for distribution (21 CFR 211.165(a))
- Review of representative number of batches (21 CFR 211.180(e)(1))
- Prepared for each batch, include complete information (21 CFR 211.188)
- Quality control unit review of records (21 CFR 211.192)
Full citation text
Testing and release for distribution (21 CFR 211.165(a))
Testing and release of drug product for distribution do not include appropriate laboratory determination of satisfactory conformance to the final specifications and identity and strength of each active ingredient prior to release.
Review of representative number of batches (21 CFR 211.180(e)(1))
Written procedures are not followed for evaluations conducted at least annually to review records associated with a representative number of batches, whether approved or rejected.
Prepared for each batch, include complete information (21 CFR 211.188)
Batch production and control records do not include complete information relating to the production and control of each batch.
Quality control unit review of records (21 CFR 211.192)
Drug product production and control records, are not reviewed and approved by the quality control unit to determine compliance with all established, approved written procedures before a batch is released or distributed.
FEI 3009461317
We match FDA inspections to companies by facility ZIP code (or city outside the US) and company name, so an inspection filed under a different name won’t appear here. FDA publishes final classifications only, and holds some back while enforcement is pending. Posted citations may differ from FDA’s final findings. FDA Data Dashboard · How we check
What Oxygen Development LLC says it offers
From Oxygen Development LLC’s own website, checked . Not verified by us.
Services
Custom formulationShow quoteHide quote“Oxygen offers both standard and customized formulations driven by:”
“Oxygen offers both standard and customized formulations driven by:”
Source page language: Italian (declared by website)
Source page · seen on
TurnkeyShow quoteHide quote“ranging from bulk manufacturing to full turnkey solutions”
“ranging from bulk manufacturing to full turnkey solutions”
Source page language: Italian (declared by website)
Source page · seen on
We read the company’s public web pages and keep a claim only when its quote appears on the page. A claim is hidden once we haven’t seen it for 120 days. Spotted something wrong? Tell us · How we collect website claims
What we checked, and what we didn’t
Confirmed from NSF’s public listing
Last checked
- NSF/ANSI 455-2 GMP certification
- 2 facility addresses
- Dosage forms in the certified scope
- Operations listed for each facility
Not verified by us
- Minimum order quantity (MOQ): the smallest order they accept
- Lead times and current capacity
- Prices
- Other certifications, like organic, kosher, halal or NSF Certified for Sport
- Whether they’re taking new clients
- Conditions inside the facility. We don’t visit or audit facilities.
- What the company’s own website says it makes and offers, shown above with quotes
Ask about these in your quote request. How we verify
Other gummy manufacturers in the United States
NSF lists 4 gummy facilities, including one in Tempe, AZ
Tempe, AZ, United States21stcenturyvitamins.com
- Capsules
- Gummies
- Softgels
- Tablets
Operations:- Kitting
- Coating
- Tablet compression
- Encapsulation
NSF/ANSI 455-2checked Nov 19, 2026NSF lists a gummy facility in Garden Grove, CA
Garden Grove, CA, United Statespackaging.com
- Capsules
- Gummies
- Powders
- Softgels
- Tablets
NSF/ANSI 455-2checked Nov 19, 2026NSF lists 2 gummy facilities, including one in St. Augustine, FL
St. Augustine, FL, United Statesactivegummy.com
- Gummies
Operations:- Molding
- Coating
NSF/ANSI 455-2checked Nov 19, 2026NSF lists a gummy facility in Merrilville, IN
Merrilville, IN, United Statesalbanesecandy.com
- Gummies
Operations:- Molding
- Liquid formulation
- Dry formulation
NSF/ANSI 455-2checked Nov 19, 2026NSF lists a gummy facility in Miami, FL
Miami, FL, United Statesalfavitamins.com
- Capsules
- Gummies
- Liquids
- Softgels
- Tablets
Operations:- Pasteurization
- Coating
- Liquid formulation
- Tablet compression
- +1 more
NSF/ANSI 455-2checked Nov 19, 2026NSF lists a gummy facility in Dallas, TX
Dallas, TX, United Statesforeverliving.com
- Gummies
- Liquids
- Powders
- Softgels
- Tablets
Operations:- Kitting
- Coating
- Liquid formulation
- Tablet compression
- +1 more
NSF/ANSI 455-2checked Nov 19, 2026